Gonorrhea: Antimicrobial Resistance and New Drugs by Queirós, Catarina Soares & Borges da Costa, João
233
Artigo de Revisão
Revista SPDV 77(3) 2019; Gonorreia: Resistência aos antimicrobianos e novos fármacos; Catarina Soares Queirós, João Borges da Costa.
Gonorreia: Resistência aos Antimicrobianos 
e Novos Fármacos      
Catarina Soares Queirós1,  João Borges da Costa1,2,3
1Serviço de Dermatovenereologia do Hospital de Santa Maria, Centro Hospitalar e Universitário de Lisboa Norte, Lisboa, Portugal
2Clínica Universitária de Dermatologia, Faculdade de Medicina de Lisboa, Lisboa, Portugal
3Instituto de Higiene e Medicina Tropical, Lisboa, Portugal
RESUMO – O impacto global das infeções sexualmente transmissívies continua a ser elevado, com significativa morbilidade e 
mortalidade associadas. A gonorreia é a segunda infeção sexualmente transmissível mais notificada na Europa, sendo que a sua 
incidência tem vindo a aumentar nos últimos anos. Apesar de tradicionalmente considerada uma infeção curável, a resistência 
da Neisseria gonorrhoeae aos antimicrobianos já se estende na atualidade aos macrólidos, tetraciclinas, combinações de sulfo-
namidas e trimetropim, quinolonas, e até mesmo ceflosporinas. Estes elevados níveis de resistência aos antimicrobianos podem 
colocar um dos maiores desafios às estratégias de prevenção e controlo das infeções sexualmente transmissíveis, ao permitirem 
a ocorrência de infeções não tratáveis no futuro. Deste modo, o desenvolvimento de novos antimicrobianos e/ou de novas com-
binações terapêuticas é uma necessidade urgente. Neste artigo é revista a evolução das resistências da Neisseria gonorrhoeae 
aos antimicrobianos ao longo dos anos, assim como os novos fármacos em desenvolvimento para o tratamento desta infeção. 
PALAVRAS-CHAVE – Antibacterianos; Doenças Bacterianas Sexualmente Transmissíveis/tratamento; Farmacorresistência Bac-
teriana; Gonorreia/tratamento; Neisseria gonorrhoeae/efeito dos medicamentos. 
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ABSTRACT – The global burden of sexually transmitted infections remains high, with significant associated morbidity and morta-
lity. Gonorrhea is the second most notified sexually transmitted infection in Europe, and its incidence has been increasing in the 
last years. Although traditionally considered a treatable infection, antimicrobial resistance of Neisseria gonorrhoeaeincludes at 
present also macrolides, tetracyclines, sulfonamides and trimethoprim combinations, quinolones, and even cephalosporins. These 
high levels of gonococcal resistance to antimicrobials resulting in untreatable infections in the future may become one of the grea-
test challenges to the prevention and control of sexually transmitted infections, which may be a significant major public health 
issue. Therefore, the development of novel antimicrobials and/or new dual antimicrobial therapy regimens is urgently needed. In 
this paper, evolution of antimicrobial resistance of Neisseria gonorrhoeae is reviewed, along with new drugs currently under deve-
lopment for the treatment of this infection.  
KEYWORDS – Bacterial Agents; Drug Resistance, Bacterial; Gonorrhea/drug therapy; Neisseria gonorrhoeae/drug effects; Se-
xually Transmitted Diseases, Bacterial/drug therapy.
1. BACKGROUND
The global burden of sexually transmitted infections 
(STIs) remains high, with more than 1 million curable STIs 
occurring each day.1 Worldwide, morbidity and mortali-
ty resulting from STIs compromise not only quality of life 
but also sexual, reproductive health and newborn health.2 
STIs also indirectly facilitate sexual transmission of HIV (by 
two to five times, in some populations) and cause cellular 
changes that precede some cancers. Left untreated, STIs can 
lead to severe complications and sequelae in both men and 
women, including pelvic inflammatory disease, infertility, 
ectopic pregnancy, miscarriage, fetal death and congeni-
tal infections.1 Therefore, STIs impose a substantial strain 
on the budgets of national health systems and negatively 
impact the overall well-being of individuals by their physi-
cal, psychological and social consequences.2 Although the 
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numbers of men and women infected with STIs are similar, 
complications disproportionately affect women in several 
ways.2,3
Gonorrhea, with 89 239 cases reported in 2017, is the 
second most notified STI in Europe, only surpassed by chla-
mydia. Incidence of Neisseria gonorrhoeae infection in Eu-
rope has also been increasing in the last years (from 8.2 per 
100 000 population in 2008 to 23 per 100 000 population 
in 2017).3 This increase is more pronounced among men, 
who have consistently higher rates of infection then women, 
and is mostly driven by increasing cases in men who have 
sex with men (MSM). This rising tendency is probably rela-
ted with increased risk behaviors, in some cases linked to 
changing sexual practices with the use of HIV pre-exposure 
prophylaxis4, increased testing among MSM (particularly at 
extra-genital sites such as the oropharynx) and the more wi-
despread use of nucleic acid amplification tests. In Portugal, 
incidence of gonorrhea is also increasing (16% increase in 
2017 comparing to 2016), with an average of 3.8 cases per 
100 000 inhabitants in 2017.5
These consistently high rates of gonorrhea in Europe are 
of particular concern if one considers the high levels of resis-
tance to antimicrobial agents, which threaten the currently 
recommended treatments and continue to be a challenge 
in STI prevention and control efforts.3 As there is no gono-
coccal vaccine, disease control relies entirely on prevention, 
diagnosis, and, most importantly, antimicrobial therapy.6
2. ANTIMICROBIAL RESISTANCE IN NG
N. gonorrhoeae is a common and preventable causative 
agent of ureteral discharge. Although considered a treata-
ble infection, high levels of gonococcal resistance to anti-
microbials may pose one of the greatest challenges to STIs 
prevention and control, by resulting in untreatable infections 
in the future, causing a significant major public health pro-
blem.1 In fact, over the past decades, N. gonorrhoeae has 
developed resistance to almost all medicines used to treat 
this infection, raising the possibility of untreatable gonococ-
cal infections.2
Antimicrobial resistance of N. gonorrhoeae appeared 
shortly after the introduction of antimicrobials, at the be-
ginning of the 20th century (Fig. 1). Factors contributing 
to increasing resistance include suboptimal diagnosis and 
surveillance capacity, easy availability of antimicrobials (in-
cluding counterfeit drugs) and lack of drug quality control. 
Moreover, N. gonorrhoeae is able to exchange DNA, espe-
cially in the pharynx, to maintain resistance genes on the 
chromosome, and to induce antigenic variations that permit 
an escape from the immune system. Together, these facts 
contributed to the rapid development of resistance.1
In 2019, resistance has extended to macrolides (in-
cluding azithromycin), tetracyclines, sulfonamides and tri-
methoprim combinations and quinolones. More recently, 
countries with good quality surveillance have also demons-
trated increased resistance to cephalosporins including ce-
fixime and ceftriaxone, the “last line” of treatment. Indeed, 
10 countries have reported treatment failure with extended-
-spectrum (third-generation) cephalosporins.1 This is parti-
cularly troublesome as extended-spectrum cephalosporins 
are currently the last remaining options for effective empiric 
first-line antimicrobial monotherapy in Europe.7
According to the WHO, first-line antimicrobial therapy 
must be highly effective, widely available and affordable, 
lack toxicity, comprise a single dose, and rapidly cure at 
least >95% of infected patients.6 Due to the observed de-
crease in susceptibility to antimicrobials in the past years,5 
European treatment guidelines now recommend combina-
tion treatment with ceftriaxone plus azithromycin as first-line 
therapy, in order to reduce the development and/or spread 
of resistance to these antimicrobials.7
3. GONOCOCCAL ANTIMICROBIAL SURVEILLAN-
CE PROGRAMME (GASP)
Monitoring the susceptibility patterns of N. gonorrhoeae 
is essential for detecting and tracking emerging resistance 
and for adjusting treatment recommendations. Since 1992, 
countries monitor the emergence of resistant strains of N. 
gonorrhoeae through “Gonococcal Antimicrobial Survei-
llance Programme” (GASP), a global laboratory network 
now including more than 60 countries. GASP monitors pat-
terns of resistance and provides data to develop treatment 
guidelines. This surveillance program monitors the longitu-
dinal trends in antimicrobial resistance (AMR) and provides 
data to inform treatment guidelines. 
European countries account for the nearly half (46%) 
of the reporting countries in 2016. Participation in GASP 
is much lower among countries in the African region, al-
though it has increased over the past few years. Despite this 
progress, the full magnitude of the problem of gonococcal 
AMR remains unknown due to a lack of data in many coun-
tries. This lack of information is particularly troublesome in 
countries with the highest gonorrhea burden and thus the 
greatest need for AMR monitoring.1
Since 2009, the European Gonococcal Antimicrobial 
Surveillance Programme (Euro-GASP), coordinated by 
the European Centre for Disease Prevention and Control 
(ECDC), aims at performing a surveillance of the susceptibi-
lity to antimicrobial agents, in order to ensure effective pa-
tient management and monitor current and emerging trends 
in antimicrobial resistance in Europe.5 
4. RESISTANCE TO TRADITIONAL ANTIMICROBIALS
4.1. Cephalosporins
Cefixime is one of the antimicrobials commonly used for 
the treatment of gonorrhea. Resistance to this agent has re-
mained stable at around 2% since 2014, and there have 
been no significant changes in cefixime minimum inhibitory 
concentration (MIC) distribution in the last few years. Ce-
fixime resistance seems to be significantly associated with 
isolates from heterosexual males compared to MSM, fe-
males compared to males, and genital isolates compared 
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to anorectal isolates. Pharyngeal isolates in general have 
significantly higher cefixime MICs (0.125-0.25 mg/L) than 
anorectal and other isolates.
Ceftriaxone is another third-generation cephalosporin 
used in the treatment of this infection. Resistance to this an-
timicrobial is rare and seems to be decreasing, with seven 
isolates in 2013, five in 2014, one in 2015 and none in 
2016 and 2017. Moreover, the MIC distribution for cef-
triaxone in 2017 shows a significantly higher proportion of 
more susceptible gonococcal isolates (MIC ≤0.016 mg/L) 
compared with the previous year, again arguing in favor of 
more susceptible isolates.5
Considering global data, 30% of the included countries 
report that >5% of specimens have decreased susceptibili-
ty to extended spectrum cephalosporins (ceftriaxone and/or 
cefixime). This problem is of particular magnitude in Asian 
countries such as Japan, South Korea, and Taiwan. 
4.2 Macrolides
Azithromycin is now recommended as first-line therapy 
for gonorrhea, in combination with ceftriaxone. Resistan-
ce to this agent has remained stable since 2014, at levels 
around 7%-8% (7.5% in 2017). The MIC distribution for azi-
thromycin also seems to be stable comparing to previous 
years, with most resistant isolates showing a MIC just above 
the breakpoint (MIC >0.5 mg/L). However, it is important 
to note that high-level resistance to azithromycin has been 
recognized, with seven cases isolated in 2016 and another 
seven in 2017. These seven isolates include one from Portu-
gal, three from Norway, two from the United Kingdom and 
one from Finland. Azithromycin resistance seems to be hi-
ghest in isolates from MSM (8.3%), followed by heterose-
xual males (7.2%), and lowest in females (6.8%). Moreover, 
azithromycin resistance seems to be significantly associated 
with isolates from those under 25 years of age compared to 
those over 25 years of age.5
Considering global data, nearly half (49%) of the inclu-
ded countries report that >5% of specimens have decreased 
susceptibility to azithromycin.
4.3. Quinolones
Ciprofloxacin is not recommended as first line therapy 
for gonorrhea. In fact, resistance levels to this antimicrobial 
remain high (46.5% in 2017), similarly to previous years. 
Resistance seems to be higher in heterosexual males (51.1%) 
comparing to MSM (41.1%), in those over 25 years old com-
paring to those under 25 years old and in the absence of 
a concurrent chlamydial infection. Moreover, ciprofloxacin 
resistance is significantly associated with genital and pha-
ryngeal infection sites comparing to anorectal isolates.5
Considering global data, 95% of the included countries 
report that >5% of specimens have decreased susceptibility 
to ciprofloxacin, with 17% of countries revealing >90% of 
resistant strains.
5. THE PROBLEM OF EXTENSIVELY DRUG-RESIS-
TANT STRAINS
The increase in N. gonorrhoeae antimicrobial resistance 
worldwide can potentially lead to a pandemic of extensively 
drug-resistant (XDR) strains, with serious public health con-
sequences. XDR strains are defined as those resistant to two 
or more of the antibiotic classes currently recommended for 
the treatment of gonorrhea, or three or more of the less fre-
quently used antibiotic classes. 
XDR strains of N. gonorrhoeae have been detected in 
multiple regions, and a large proportion of the circula-
ting strains worldwide are very close to transform into XDR 
strains.8 To prevent the emergence of drug resistant strains, 
Figure 1 - Introduction of new antimicrobials and subsequent development of resistances (XDR stands for extensively drug resistant).
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WHO now recommends dual therapy with ceftriaxone plus 
azithromycin.1
6. NEW DRUGS IN PERSPECTIVE
As the emergence of drug resistance seems to be uns-
toppable, new treatment options are necessary in order 
to control gonorrhea. One possible approach is to assess 
whether older drugs, such as gentamicin and spectinomy-
cin, may be used in novel combinations for treatment of 
gonorrhea.9 Another option is the development of new an-
timicrobials.6
6.1. Already Existing Antimicrobials
Sitafloxacin is a new-generation broad spectrum fluoro-
quinolone, mostly used for respiratory infections. According 
to recent studies, it seems to be a good candidate to be 
included in dual antimicrobial therapy for gonorrhea, parti-
cularly in cases of cephalosporin resistance or allergy. Dela-
floxacin is another fluoroquinolone currently being studied 
for the treatment of gonorrhea, although more studies are 
required to correlate its promising in vitro results with clinical 
treatment outcomes. Novel combinations of previously exis-
ting antimicrobials have also been tested in recent studies, 
with five of them showing promise in the treatment of gonor-
rhea. These include gentamicin + ertapenem, moxifloxacin 
+ ertapenem, spectinomycin + ertapenem, azithromycin 
+ moxifloxacin, and cefixime + gentamicin. Gentamicin is 
an aminoglycoside already included in several guidelines 
in combination with azithromycin, as an alternative treat-
ment when first-line therapies fail. Recently, gentamicin has 
shown promise when used in combination with ertapenem 
or cefixime, with high levels of efficacy and synergism.6
6.2. New Antimicrobials
Ideally, new antimicrobials should belong to antibacterial 
families different to the ones already included in treatment 
guidelines, in order to delay the appearance of resistances 
as much as possible (Table 1). Currently, only three molecu-
les in this category have reached clinical trials: solithromy-
cin, zoliflodacin, and gepotidacin.6
Solithromycin is a broad-spectrum oral fluoroketolide 
which targets three prokaryotic ribosomal sites.10 In vitro stu-
dies have demonstrated promising results, with more activi-
ty against N. gonorrhoeae than the antimicrobials currently 
recommended for its treatment. Phase II clinical trials were 
concluded with 100% efficacy in the treatment of men and 
women in all studied sites (genital, oral, and rectal).10 The 
drug is currently in phase III trials.6
Zoliflodacin has a novel mechanism of action, by inhibi-
ting the spiropyrimidinetrione topoisomerase. Early in vitro 
studies showed promising results, with the compound being 
highly effective against isolates from 21 European coun-
tries.11 Zoliflodacin also did not present any cross-resistance 
to other antimicrobials.11,12
Finally, gepotidacin is a novel triazacenaphthylene anti-
bacterial which inhibits bacterial DNA gyrase and topoiso-
merase IV via a unique mechanism. The compound showed 
no antagonism when combined with levofloxacin, azi-
thromycin, tetracycline, and ceftriaxone; the combination of 
gepotidacin with moxifloxacin had a synergistic effect. This 
drug underwent a phase II evaluation, showing that oral ge-
potidacin was more than 95% effective in treating uncompli-
cated urogenital gonorrhea.13
Apart from these three drugs in clinical trials, other 
compounds are still in early experimental phases. This is 
the case of lefamulin, a novel semi-synthetic pleuromutilin 
that has showed potent activity against gonococcal isolates 
and no significant cross-resistance to other antimicrobials. 
Furthermore, this compound has also proved to be active 
against other relevant bacterial pathogens causing STIs, na-
mely Chlamydia trachomatis and Mycoplasma genitalium.14 
Aminoethyl spectinomycins belong to a new class of se-
misynthetic analogs of the antibiotic spectinomycin, currently 
being studied for the treatment of drug-resistant gonococci. 
Table 1 - New antimicrobials undergoing evaluation for treatment of gonorrhea and summary of their 
mechanism of action. 
ANTIMICROBIAL CLASS MECHANISM OF ACTION
Solithromycin
Broad-spectrum oral fluoroketolide Inhibits bacterial translation by binding to three 
prokaryotic ribosomal sites of 23S ribosomal RNA
Zoliflodacin
Hydroquinoline Inhibits the spiropyrimidinetrione topoisomerase 
(type II)
Gepotidacin
Triazacenaphthylene Inhibits bacterial DNA replication through a unique 
interaction on the bacterial subunits of DNA gyrase 
(GyrA) and topoisomerase IV (ParC)
Lefamulin
Semi-synthetic pleuromutilin Inhibits protein synthesis by binding to the peptidyl 
transferase center of the 50S bacterial ribosome, 
thus preventing the binding of transfer RNA
Aminoethyl spectinomycins
Semi-synthetic analogs of spectinomycin Inhibits protein synthesis by binding to the 30S 
ribosomal subunit
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Although more studies are needed, they seem a promising 
alternative for spectinomycin and antibiotics such as ceftria-
xone against drug-resistant gonorrhea.15 As with lefamulin, 
these agents also seem to be active against other relevant 
bacterial pathogens in STIs, such as Chlamydia trachomatis 
and Mycoplasma genitalium.
7. PUBLIC HEALTH IMPLICATIONS AND FUTURE 
STRATEGIES
In order to achieve the goal of controlling sexually trans-
mitted infection epidemics as a public health concern, seve-
ral targets have been defined by the WHO. These include 
that, by 2020, 70% of countries report on antimicrobial re-
sistance in N. gonorrhoeae, and that, by 2030, the inciden-
ce of infections with N. gonorrhoeae would have fallen by 
90% globally.2
To achieve this goal, a critical component of the Global 
STI Strategy is strengthening STI surveillance and program 
monitoring systems.1 There is an urgent need to strengthen 
prevention activities aimed at increase testing in individuals 
at highest risk. This could be achieved by targeting speci-
fic risk groups with evidence-based messages and methods. 
Social media and apps should be considered for prevention 
campaigns in addition to traditional approaches.3 Overall, 
stronger surveillance is needed to better characterize the ex-
tent of antimicrobial resistance among gonococcal strains.
The potential impact of the introduction of pre-exposure 
prophylaxis of HIV infection in different communities should 
also be monitored, including through the surveillance of 
STIs, sexual behaviors and drug resistance. The increasing 
use of DNA amplification assays should also be viewed with 
caution, as it does not allow yet traditional antimicrobial 
susceptibility testing.
CONCLUSION
The continuing low cephalosporin resistance in Europe 
is promising, considering that these are the last remaining 
options for empiric first-line monotherapy. Monitoring is ne-
vertheless needed as XDR strains from Southeast Asia can be 
imported through migration and sexual tourism. Due to the 
high levels of documented resistance, neither azithromycin 
nor ciprofloxacin are currently recommended for gonorrhea 
monotherapy, unless the isolates are first shown to be sus-
ceptible. 
In previous years, there has been a tendency for MSM to 
have a lower risk of harboring antimicrobial resistant isola-
tes,16 which is concordant with a lower risk of antimicrobial 
resistance among anorectal isolates.
Although European overall resistance levels seem to be 
stable for all antimicrobials, the response plan to control the 
threat of multidrug-resistant N. gonorrhoeae in Europe,17 
which is currently under revision, should continue to be obser-
ved to help identify and report treatment failures and ensure 
that gonorrhea remains a treatable infection. In addition, the 
development of novel antimicrobials and/or new dual antimi-
crobial therapy regimens is urgently needed.
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